Literature DB >> 24820963

The clinical and integrated management of COPD.

G Bettoncelli1, F Blasi, V Brusasco, S Centanni, A Corrado, F De Benedetto, F De Michele, G U Di Maria, C F Donner, F Falcone, C Mereu, S Nardini, F Pasqua, M Polverino, A Rossi, C M Sanguinetti.   

Abstract

COPD is a chronic pathological condition of the respiratory system characterized by persistent and partially reversible airflow obstruction, to which variably contribute remodeling of bronchi (chronic bronchitis), bronchioles (small airway disease) and lung parenchyma (pulmonary emphysema). COPD can cause important systemic effects and be associated with complications and comorbidities. The diagnosis of COPD is based on the presence of respiratory symptoms and/or a history of exposure to risk factors, and the demonstration of airflow obstruction by spirometry. GARD of WHO has defined COPD "a preventable and treatable disease". The integration among general practitioner, chest physician as well as other specialists, whenever required, assures the best management of the COPD person, when specific targets to be achieved are well defined in a diagnostic and therapeutic route, previously designed and shared with appropriateness. The first-line pharmacologic treatment of COPD is represented by inhaled long-acting bronchodilators. In symptomatic patients, with pre-bronchodilator FEV1 < 60%predicted and ≥ 2 exacerbations/year, ICS may be added to LABA. The use of fixed-dose, single-inhaler combination may improve the adherence to treatment. Long term oxygen therapy (LTOT) is indicated in stable patients, at rest while receiving the best possible treatment, and exhibiting a PaO2 ≤ 55 mmHg (SO2<88%) or PaO2 values between 56 and 59 mmHg (SO2 < 89%) associated with pulmonary arterial hypertension, cor pulmonale, or edema of the lower limbs or hematocrit > 55%. Respiratory rehabilitation is addressed to patients with chronic respiratory disease in all stages of severity who report symptoms and limitation of their daily activity. It must be integrated in an individual patient tailored treatment as it improves dyspnea, exercise performance, and quality of life. Acute exacerbation of COPD is a sudden worsening of usual symptoms in a person with COPD, over and beyond normal daily variability that requires treatment modification. The pharmacologic therapy can be applied at home and includes the administration of drugs used during the stable phase by increasing the dose or modifying the route, and adding, whenever required, drugs as antibiotics or systemic corticosteroids. In case of patients who because of COPD severity and/or of exacerbations do not respond promptly to treatment at home hospital admission should be considered. Patients with "severe or "very severe COPD who experience exacerbations should be carried out in respiratory unit, based on the severity of acute respiratory failure. An integrated system is required in the community in order to ensure adequate treatments also outside acute care hospital settings and rehabilitation centers. This article is being simultaneusly published in Multidisciplinary Respiratory Medicine 2014; 9:25.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24820963

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  6 in total

Review 1.  Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids?

Authors:  Andrea P Rossi; Erika Zanardi; Mauro Zamboni; Andrea Rossi
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

2.  lncRNA GAS5 promotes pyroptosis in COPD by functioning as a ceRNA to regulate the miR‑223‑3p/NLRP3 axis.

Authors:  Rubing Mo; Jing Li; Yongxing Chen; Yipeng Ding
Journal:  Mol Med Rep       Date:  2022-05-18       Impact factor: 3.423

Review 3.  Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies.

Authors:  Andrea Rossi; Bojana Butorac-Petanjek; Marco Chilosi; Borja G Cosío; Matjaz Flezar; Nikolaos Koulouris; José Marin; Neven Miculinic; Guido Polese; Miroslav Samaržija; Sabina Skrgat; Theodoros Vassilakopoulos; Andrea Vukić-Dugac; Spyridon Zakynthinos; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-08-29

Review 4.  Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis.

Authors:  Fabiano Di Marco; Giovanni Sotgiu; Pierachille Santus; Denis E O'Donnell; Kai-Michael Beeh; Simone Dore; Maria Adelaide Roggi; Lisa Giuliani; Francesco Blasi; Stefano Centanni
Journal:  Respir Res       Date:  2018-01-24

Review 5.  Sphingosine 1-Phosphate: A Novel Target for Lung Disorders.

Authors:  Sabira Mohammed; K B Harikumar
Journal:  Front Immunol       Date:  2017-03-14       Impact factor: 7.561

6.  Spirometry evaluation to assess performance of a claims-based predictive model identifying patients with undiagnosed COPD.

Authors:  Chad Moretz; Srinivas Annavarapu; Rakesh Luthra; Seth Goldfarb; Andrew Renda; Asif Shaikh; Shuchita Kaila
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-02-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.